Trump Urges Intel CEO to Resign, Calls Him ‘Conflicted'
'The CEO of INTEL is highly CONFLICTED and must resign, immediately,' Trump wrote on Truth Social Thursday. 'There is no other solution to this problem. Thank you for your attention to this problem!'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?
Key Points Hims & Hers Health continues to post robust growth. Shares sold off, however, after revenue missed analyst expectations. The stock is still reasonably valued given its growth prospects. 10 stocks we like better than Hims & Hers Health › Hims & Hers Health (NYSE: HIMS) is one of the most volatile stocks on the market at the moment, prone to big swings in either direction. This is true even intraday, as the stock plunged following the company's second-quarter results, only to rally back, only to plunge again. As of this writing, the stock is still trading up more than 130% this year. Let's take a closer look at the most recent earnings results for this telehealth company focused on providing accessible and affordable healthcare solutions for various health and wellness needs, and its prospects. Who knows, you might want to jump in on this somewhat volatile growth stock. Hims saw strong revenue growth in Q2 Hims & Hers continued to deliver outstanding revenue growth in Q2, with sales climbing 73% year over year to $544.8 million. That was toward the high end of its forecast for revenue of $530 million to $550 million, but it missed analyst expectations for revenue of $552 million. Monthly online revenue per subscriber jumped 30% to $74 per month, while the number of subscribers climbed 31% to nearly 2.44 million. The company said that the number of subscribers in both oral weight loss and dermatology grew more than 55% in the quarter. Customers using at least one personalized subscription increased by 89% to 1.5 million, representing more than 60% of the Hims & Hers subscriber base. It said that 70% of new patients who join the platform use a personalized treatment plan, and that the number of subscribers using a personalized treatment plan to treat multiple conditions skyrocketed 170% to more than 500,000. Revenue from GLP-1 weight loss drugs fell from $230 million in Q1 to $190 million in Q2, after Novo Nordisk ended a partnership with the telehealth company. Nonetheless, it still expects to generate $725 million of revenue this year from weight loss drugs, led by oral weight loss products and personalized doses. Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending jumped 50% to nearly $218 million. Marketing expenses took up 40% of revenue in the quarter, though that was down from 46% a year ago, so the company continues to see leverage in this area despite the increased spending. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) surged to $82.2 million from $39.3 million a year ago. Adjusted earnings per share (EPS) came in at $0.17, topping the $0.15 analyst consensus as compiled by LSEG. Metric Q1 Results Growth (YOY) Revenue $544.8 million 73% Monthly online revenue per subscriber $74 30% Subscribers 2.44 million 31% Adjusted EBITDA $82.2 million 109% Adjusted EPS $0.17 183% Marketing expense $231 million 77% Marketing as % of revenue 40% (600 basis points) Gross margin 76% (500 basis points) Data source: Hims & Hers Health. YOY = year over year. Looking ahead, Hims & Hers maintained its forecast for 2025 revenue to be between $2.3 billion and $2.4 billion, equal to growth of 56% to 63%. It also kept its adjusted EBITDA guidance of $295 million to $335 million. For Q3, it projected revenue of between $570 million and $590 million, and adjusted EBITDA of $60 million to $70 million. The company is starting to look toward international expansion to bolster growth. It will begin by focusing on Canada next year, while its acquisition of Zava in July will help it expand into Europe. It also anticipates entering the Latin American and Asian markets in the coming years. Hims & Hers also continues to expand into new areas. It will launch hormonal health soon, starting with lab testing. The company believes this will help it reach its targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA in 2030. Is the stock a buy? Hims & Hers continues to be a growth engine. Even though there's been some disruption from its spat with Novo Nordisk, it is still seeing strong growth across different health categories. With the company moving into new areas, like hormonal health and longevity, and looking to expand internationally, it has a lot of growth opportunities ahead. Meanwhile, with the majority of its subscribers on personalized treatment plans, it has a pretty sticky user base. From a valuation standpoint, the stock trades at a forward price-to-earnings (P/E) ratio of around 55 based on the analyst consensus for 2025. But its forward price/earnings-to-growth ratio (PEG) is under 0.6, and stocks with PEG ratios below 1 are usually considered undervalued. Given that it operates a subscription business with high gross margins, you can also look at the stock from a price-to-sales perspective; on that front, it trades at a multiple of 5.5 times 2025 analyst estimates. Overall, I'd say, based on the type of business the company is in, that it's still reasonably priced. However, it's still a volatile stock that carries some risk depending on what happens in the weight loss segment. Still, I really like its international opportunity, and think Hims & Hers Health could have solid long-term upside from here. Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills? was originally published by The Motley Fool 登入存取你的投資組合
Yahoo
6 minutes ago
- Yahoo
Mohamed Salah challenges Uefa response to Palestinian footballer's death in Gaza
Liverpool forward Mohamed Salah has called out Uefa for not saying how a footballer known as the 'Palestinian Pele' died in its tribute to him. The Palestinian Football Association (PFA) said on Wednesday that Suleiman Al-Obeid, 41, died in an Israeli attack in Gaza. In an X post, European football association Uefa said he was 'a talent who gave hope to countless children, even in the darkest of times'. Responding to this, Egyptian star Salah said: 'Can you tell us how he died, where, and why?' Among those who praised his response was former Labour leader Jeremy Corbyn, who replied: 'Well said Mo!' Salah, 33, who has more than 19 million X followers, previously called for the massacres in the conflict to stop and for aid to be allowed into Gaza. In a video posted on Instagram in October 2023, he said: 'It is not always easy to speak in times like this. There has been too much violence and too much heartbreak and brutality. 'The escalations in the recent weeks is unbearable to witness. All lives are sacred and must be protected. The massacres need to stop. Families are being torn apart.' The PFA said that Al-Obeid, who was married with two sons and three daughters, made 24 appearances for the national team, scoring twice. He was nicknamed the 'Palestinian Pele', the PFA said. The Israel Defence Forces (IDF) has been approached for comment.
Yahoo
6 minutes ago
- Yahoo
If You'd Invested $1,000 in Palantir Stock 3 Years Ago, Here's How Much You'd Have Today
Key Points Palantir's AIP contributed to accelerated revenue growth. Its growth has led to a pricey valuation, making its near-term direction less certain. 10 stocks we like better than Palantir Technologies › Palantir Technologies (NASDAQ: PLTR) stock has been on a tear since last year's U.S. presidential election. Since the election on Nov. 5, the stock is up by about 250%. While that is a considerable return, it is relatively modest compared to how the stock has performed over the last three years, when the market and Palantir were in the middle of a bear market. Amid the rising popularity of AI and its productivity solution, Palantir's returns since that time are nothing short of eye-popping. Palantir over the last three years If one had bought Palantir on Aug. 8, 2022, a $1,000 investment would be worth about $15,700 today. Three years ago, a dramatic pullback from the highs of the 2021 bull market left Palantir trading below $10 per share, the approximate level where it sold on its first day of trading on Sept. 30, 2020. Additionally, it got off to a slow start as it briefly fell below $6 per share in December 2022. Nonetheless, Palantir began moving higher in 2023, particularly after Open AI's release of an upgraded version of ChatGPT put the spotlight on generative AI. Palantir responded with its own generative AI solution, the artificial intelligence platform (AIP), in April 2023. Customers began reporting massive productivity gains. Over time, the stock's growth accelerated as revenue growth began to rise at a significantly faster rate. Consequently, the stock reached stratospheric highs, with a P/E ratio approaching 600. Although such earnings multiples can be common with growth stocks, its price-to-sales (P/S) ratio of 130 all but verifies that the market has priced the stock for perfection. That increases the odds of a dramatic fall at the slightest hint of bad news. However, few can deny the success of Palantir's investors over the last three years. Even if its near-term prospects are less clear, Palantir should succeed long term, since its tools have delivered massive productivity gains for its customers. Should you invest $1,000 in Palantir Technologies right now? Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Will Healy has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Palantir Technologies. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in Palantir Stock 3 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool
